Cargando…
Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
BACKGROUND: Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two other major global pathogens, Leishmania spp., res...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850312/ https://www.ncbi.nlm.nih.gov/pubmed/20386598 http://dx.doi.org/10.1371/journal.pntd.0000651 |
_version_ | 1782179765785985024 |
---|---|
author | Chen, Chiung-Kuang Leung, Siegfried S. F. Guilbert, Christophe Jacobson, Matthew P. McKerrow, James H. Podust, Larissa M. |
author_facet | Chen, Chiung-Kuang Leung, Siegfried S. F. Guilbert, Christophe Jacobson, Matthew P. McKerrow, James H. Podust, Larissa M. |
author_sort | Chen, Chiung-Kuang |
collection | PubMed |
description | BACKGROUND: Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two other major global pathogens, Leishmania spp., responsible for leishmaniasis, and Trypansoma brucei, the causative agent of African Sleeping Sickness. Both T. cruzi and Leishmania parasites have an essential requirement for ergosterol, and are thus vulnerable to inhibitors of sterol 14α-demethylase (CYP51), which catalyzes the conversion of lanosterol to ergosterol. Clinically employed anti-fungal azoles inhibit ergosterol biosynthesis in fungi, and specific azoles are also effective against both Trypanosoma and Leishmania parasites. However, modification of azoles to enhance efficacy and circumvent potential drug resistance has been problematic for both parasitic and fungal infections due to the lack of structural insights into drug binding. METHODOLOGY/PRINCIPAL FINDINGS: We have determined the crystal structures for CYP51 from T. cruzi (resolutions of 2.35 Å and 2.27 Å), and from the related pathogen T. brucei (resolutions of 2.7 Å and 2.6 Å), co-crystallized with the antifungal drugs fluconazole and posaconazole. Remarkably, both drugs adopt multiple conformations when binding the target. The fluconazole 2,4-difluorophenyl ring flips 180° depending on the H-bonding interactions with the BC-loop. The terminus of the long functional tail group of posaconazole is bound loosely in the mouth of the hydrophobic substrate binding tunnel, suggesting that the major contribution of the tail to drug efficacy is for pharmacokinetics rather than in interactions with the target. CONCLUSIONS/SIGNIFICANCE: The structures provide new insights into binding of azoles to CYP51 and mechanisms of potential drug resistance. Our studies define in structural detail the CYP51 therapeutic target in T. cruzi, and offer a starting point for rationally designed anti-Chagasic drugs with improved efficacy and reduced toxicity. |
format | Text |
id | pubmed-2850312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-28503122010-04-12 Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole Chen, Chiung-Kuang Leung, Siegfried S. F. Guilbert, Christophe Jacobson, Matthew P. McKerrow, James H. Podust, Larissa M. PLoS Negl Trop Dis Research Article BACKGROUND: Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two other major global pathogens, Leishmania spp., responsible for leishmaniasis, and Trypansoma brucei, the causative agent of African Sleeping Sickness. Both T. cruzi and Leishmania parasites have an essential requirement for ergosterol, and are thus vulnerable to inhibitors of sterol 14α-demethylase (CYP51), which catalyzes the conversion of lanosterol to ergosterol. Clinically employed anti-fungal azoles inhibit ergosterol biosynthesis in fungi, and specific azoles are also effective against both Trypanosoma and Leishmania parasites. However, modification of azoles to enhance efficacy and circumvent potential drug resistance has been problematic for both parasitic and fungal infections due to the lack of structural insights into drug binding. METHODOLOGY/PRINCIPAL FINDINGS: We have determined the crystal structures for CYP51 from T. cruzi (resolutions of 2.35 Å and 2.27 Å), and from the related pathogen T. brucei (resolutions of 2.7 Å and 2.6 Å), co-crystallized with the antifungal drugs fluconazole and posaconazole. Remarkably, both drugs adopt multiple conformations when binding the target. The fluconazole 2,4-difluorophenyl ring flips 180° depending on the H-bonding interactions with the BC-loop. The terminus of the long functional tail group of posaconazole is bound loosely in the mouth of the hydrophobic substrate binding tunnel, suggesting that the major contribution of the tail to drug efficacy is for pharmacokinetics rather than in interactions with the target. CONCLUSIONS/SIGNIFICANCE: The structures provide new insights into binding of azoles to CYP51 and mechanisms of potential drug resistance. Our studies define in structural detail the CYP51 therapeutic target in T. cruzi, and offer a starting point for rationally designed anti-Chagasic drugs with improved efficacy and reduced toxicity. Public Library of Science 2010-04-06 /pmc/articles/PMC2850312/ /pubmed/20386598 http://dx.doi.org/10.1371/journal.pntd.0000651 Text en Chen et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Chen, Chiung-Kuang Leung, Siegfried S. F. Guilbert, Christophe Jacobson, Matthew P. McKerrow, James H. Podust, Larissa M. Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole |
title | Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole |
title_full | Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole |
title_fullStr | Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole |
title_full_unstemmed | Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole |
title_short | Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole |
title_sort | structural characterization of cyp51 from trypanosoma cruzi and trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850312/ https://www.ncbi.nlm.nih.gov/pubmed/20386598 http://dx.doi.org/10.1371/journal.pntd.0000651 |
work_keys_str_mv | AT chenchiungkuang structuralcharacterizationofcyp51fromtrypanosomacruziandtrypanosomabruceiboundtotheantifungaldrugsposaconazoleandfluconazole AT leungsiegfriedsf structuralcharacterizationofcyp51fromtrypanosomacruziandtrypanosomabruceiboundtotheantifungaldrugsposaconazoleandfluconazole AT guilbertchristophe structuralcharacterizationofcyp51fromtrypanosomacruziandtrypanosomabruceiboundtotheantifungaldrugsposaconazoleandfluconazole AT jacobsonmatthewp structuralcharacterizationofcyp51fromtrypanosomacruziandtrypanosomabruceiboundtotheantifungaldrugsposaconazoleandfluconazole AT mckerrowjamesh structuralcharacterizationofcyp51fromtrypanosomacruziandtrypanosomabruceiboundtotheantifungaldrugsposaconazoleandfluconazole AT podustlarissam structuralcharacterizationofcyp51fromtrypanosomacruziandtrypanosomabruceiboundtotheantifungaldrugsposaconazoleandfluconazole |